World Cancer Conference | Event Agenda
20 - 22 November, 2008, Beijing International Hotel, China

Event Agenda Day One | Thursday 20th November, 2008 08:00 Morning coffee and registration 08:30 Welcome from organiser 08:35 Chairman Opening remarks 08:45 Opening address from Guest of Honour Prof Huang Jie-Fu, Vice Minister, Ministry of Public Health, China CANCER CONTROL & TREATMENT DEVELOPMENTS 09:00 Organ transplant- development as a novel treatment for liver cancer Overview of liver transplants in Asia: past experience, current status & future developments Combining radiation, chemotherapy with liver transplant to improve survival rates Pre-surgery evaluation: key factors for the decision making process LDLT for liver cancer treatment in China Prof Huang Jie-Fu, Vice Minister, Ministry of Public Health, China 09:35 Overview of cancer disease control & prevention initiatives in China Epidemiology overview of cancer disease in China Government initiatives for cancer prevention, diagnosis& treatment Public private partnership practice for cancer control in China Kong Ling Zhi, Deputy Director of Disease Control Department, Ministry of Public Health, China 10:10 International perspective: Cancer Control in France & the War on Cancer Plan 2003-2008 Prof David Khayat, Head of Medical Oncology, Salpetriere Hospital & Former President, French National Cancer Institute 10:45 Morning refreshment & poster/exhibition viewing time EPIDEMIOLOGY & PREVENTION 11:15 Epidemiology and prevention of hepatitis associated hepatocellular carcinoma – a worldwide translational approach A meta-analysis on the seroprevalence of HBsAg and anti-HCV antibodies in 27 881 hepatocellular carcinomas from 90 studies confirmed wide international variations. A predominance of HBsAg was found in hepatocellular carcinomas from most Asian, African and Latin American countries, but anti-HCV predominated in Europe, North America, Japan, Pakistan, Mongolia, and Egypt. Anti-HCV was found more often than HBsAg in Europe and the United States. 25 years after having been licensed, HBV vaccination programs are now carried out in 158 countries, but they have yet to reach many high-risk populations in sub-Saharan Africa and Asia. In the absence of a vaccine, the prevention of HCV infection requires an integrated strategy (ie, screening of blood donations, safe injection practices and avoidance of unnecessary injections). Syed Ahsan Raza, MD MSc, Senior Instructor, Research Department of Surgery, The Aga Khan University 11:50 The modulating role 5-LOX in the carcinogenic action of cigarette smoke and its active component in colon cancer Substantial evidence indicates that cigarette smoke exposure is a risk factor for colorectal cancer. We investigated the modulating role of cigarette smoke and its active component NNK, in 5-LOX expression and expression of 5-LOX in SW1116 colon cancer cells. It also promoted 5-LOX DNA de-methylation. NNK stimulated colon cancer cell proliferation, enhanced α7-nAChR mRNA level, NF-қB DNA binding activity, 5-LOX and COX-2 expression. Inhibitors of COX-2 and 5-LOX inhibited tumor growth in nude mice. The present study demonstrates the central role of 5-LOX in the carcinogenic action of cigarette smoke and NNK on colon cancer. Prof Cho Chi Hin, Professor of Pharmacology & Chairman, Department of Pharmacology, Faculty of Medicine, The Chinese University of Hong Kong 12:25 Technology tutorial: Technology and product providers will provide interactive educational tutorials which address the benefit of their technology or product in the field of cancer diagnostics, prognosis analysis & treatment development. If you would like to host a tutorial, please contact linda.wan@ibcchina.com.cn 12:45 Luncheon & poster/exhibition viewing time DISEASE MANAGEMENT & TREATMENT INNOVATION I 14:00 Advances in Surgical Management of Esophageal Cancer Esophageal Cancer is one of the most common cancer types in China and fourth killer of cancer in Chinese population. Even there are quite a lot of new drugs & therapies developed in this area, surgical operation is still the most mature treatment for esophageal carcinoma. In the session, Dr He Jie will share you his research& insights in surgical management of this common disease in Asia. Prof He jie, Chief of Thoracic Surgical Oncology, Vice President, Cancer Institute & Hospital, Chinese Academy of Medical Sciences 14:35 Treatment for advanced non-small cell lung cancer While there have been advances in the treatment of lung cancer, they have been marginal with recent advances in the chemotherapy and molecularly targeted treatment of breast, colorectal and genitourinary cancers. Lung cancer is extremely difficult to treat, obtain positive results and develop new standard treatments. The results of clinical trials on gefitinib and erlotinib suggest that the evaluation of molecular target drugs is quite difficult in unselected patient population and may be different from cytotoxic drugs. We need to identify specific molecular biomarkers for each drug. In view of global studies, it will be essential to obtain more significant results by sophisticated clinical trials in selected patient populations and contribute to improving the treatment outcome of lung cancer patients. Prof Nagahiro Saijo, M.D., Ph.D, President, International Association for Study of Lung Cancer; President, Japanese Society of Medical Oncology & Deputy Director, National Cancer Center Hospital East, Japan 15:10 U pdates and future development of neoadjuvant chemotherapy for breast cancer Prof Wu Shi Kai, Deputy Director, Department of Breast Cancer, 307 Hospital, Academy of Military Medicine Sciences, China 15:45 Afternoon refreshment & poster/exhibition viewing time CLINICAL TRIALS IN CHINA 16:15 Phase III/IV clinical trial in China for better treatment Current regulation guidelines for phase III/IV trial patient recruitment Ethical issues in trial design & operation process Experiences from Western countries 16:50 Clinical challenges of cancer drug combinations Assessing combination therapies Obtaining accurate dose response information Calculating maximum tolerated dosage and biological effective dosage Lessons learned from real-life experiences 17:25 Chairman’s remarks & close of conference day 1 17:30 Networking cocktail reception Day Two | Friday 21st November, 2008 08:30 Morning coffee & tea DISEASE MANAGEMENT & TREATMENT INNOVATION II 09:00 Progress on advanced colorectal cancer Prof David Khayat, Head of Medical Oncology, Salpetriere Hospital & Former President, French National Cancer Institute 09:35 Clinical practice advance for liver cancer management Prof Zhang Yangde, President, National Hepatobiliary & Enteric Surgery Research Center, Ministry of Health 10:10 Treatment development for gastric cancer Prof Alex Y. Chang, Chief Executive Officer & Medical Director, John Hopkins Singapore International Medical Centre (Invited) 10:45 Morning refreshment & poster/exhibition viewing time CANCER BIOMARKERS & DIAGNOSTICS 11:15 Development and implementation of assays in cancer care Although increasingly important for targeted and personalized therapies in the cancer patient, the development and validation of useful biomarkers is often stopped by inadequate assay development. The Cancer Diagnosis Program of the National Cancer Institute has identified multiple needs for assay development that include: specimen acquisition, access to standards and reagents, education on assay development, support for improving assay performance and validation for clinical use. This session will focus on making assays robust and validated for predicting response to therapy and monitoring molecular recurrence. Dr J. Milburn Jessup, Chief of Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD, National Cancer Institute, USA 11:50 Circulating tumor cells (CTC) as a prognostic and predictive indicator in advanced lung cancer patients Scientists have long believed that circulating tumor cells held a wealth of information. This study has shown that negative enrichment immunomagnetic-based technology plays a definitive role in predicting and judging prognosis of lung cancer patients. CTC will go a long way towards addressing an unmet need in the cancer field and could change the course of treatment for many critically ill patients. Prof Zhou Xiao-Yun, Department of Respiratory Diseases, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences 12:25 Technology tutorial: Technology and product providers will provide interactive educational tutorials which address the benefit of their technology or product in the field of cancer diagnostics, prognosis analysis& treatment development. If you would like to host a tutorial, please contact linda.wan@ibcchina.com.cn 12:45 Luncheon & poster/exhibition viewing time SUPPORTIVE CARE 14:00 Erythropoietin, where do we stand now? Controversies 2007-2008 Epo- receptor determination on cancer cells: what do they imply? Induction of progression of the cancer clone? How to use erythropoietins in the clinic: advantages and risks Dr Mario Dicato, Hematologist-Oncologist, Centre Hospitalier de Luxembourg 14:35 Clinical nutrition support during cancer treatments Malnutrition is the commonest co-morbidity associated with cancer and a substantial proportion of cancer patients die from cachexia. Patients with cancer in the digestive tract, respiratory tract and head and neck regions are at greatest risk of developing malnutrition. Malnutrition suppresses immunity, delays tissue repair and promotes the loss of muscle mass and hypoproteinemia which results in increased morbidity, mortality, hospital stay and costs. As a result, intensive nutritional support was used to improve the immediate and long term outcomes of cancer treatment. The results of most randomized clinical trials have not been remarkable. Paradoxically, routine use of parenteral nutrition during cytotoxic therapies can result in net harm. Benefit has been demonstrated in preoperative parenteral nutrition in patients undergoing curative surgery for cancer of the upper gastrointestinal tract. In general, all cancer patients should be assessed for malnutrition at initial presentation. At the same time, it is essential that medical and paramedical oncology staff maintain an active interest in nutrition support to ensure maximal benefits from the intervention. Prof Mohandas Mallath, Head of Dept. Digestive Diseases& Clinical Nutrition, Tata Memorial Hospital, & Dean-Academic, Tata Memorial Centre, India 15:10 Afternoon refreshment & poster/exhibition viewing time ROUND TABLE DISCUSSION 15:40 Emerging technologies & economic realities: can we afford the bill for modern cancer care? Over the past two decades, new technologies such as PET/CT, radiotherapy, mAbs & biological drugs bring us better hope for cancer treatment. However, the cost of cancer treatment has significantly increased. During this interactive roundtable debate, we will discuss how to implement best therapy to your patient with a cost effective plan. 16:15   Chairman’s remarks & end of conference   Please download the free brochure for more details.

Find out more overview | Sponsorship and Exhibition Opportunities | Registration Fees | Event Agenda | Download Brochure Terms & Conditions | Product Enquiry